Neurosense Therapeutics Ltd

자세한 내용은 Neurosense Therapeutics Ltd 회사

NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease

회사 정보

종목 코드 NRSN

회사 이름Neurosense Therapeutics Ltd

상장일Dec 09, 2021

CEOMr. Alon Ben-Noon

직원 수15

유형Ordinary Share

회계 연도 종료Dec 09

주소11 Hamenofim St.

도시HERZLIYA

증권 거래소NASDAQ Capital Market Consolidated

국가Israel

우편 번호4672562

전화97299531142

웹사이트https://www.neurosense-tx.com/

종목 코드 NRSN

상장일Dec 09, 2021

CEOMr. Alon Ben-Noon

회사 임원

이름

이름/직위

직위

주식 보유

변동

Mr. Alon Ben-Noon

Chief Executive Officer, Director

3.18M

+3.04%

Mr. Or Eisenberg

Chief Financial Officer

480.92K

+4.55%

Dr. Ferenc Tracik

Chief Medical Officer

189.62K

+54.22%

Mr. Mark W. Leuchtenberger

Independent Non-Executive Chairman of the Board

64.00K

--

Mr. Cary J. Claiborne

Non-Executive Independent Director

24.00K

--

Dr. Revital Mandil-Levin, Ph.D.

Non-Executive Independent Director

--

Ms. Christine A. Pellizzari, J.D.

Non-Executive Independent Director

--

Ms. Caren Deardorf

Non-Executive Independent Director

--

이름

이름/직위

직위

주식 보유

변동

Mr. Alon Ben-Noon

Chief Executive Officer, Director

3.18M

+3.04%

Mr. Or Eisenberg

Chief Financial Officer

480.92K

+4.55%

Dr. Ferenc Tracik

Chief Medical Officer

189.62K

+54.22%

Mr. Mark W. Leuchtenberger

Independent Non-Executive Chairman of the Board

64.00K

--

Mr. Cary J. Claiborne

Non-Executive Independent Director

24.00K

--

Dr. Revital Mandil-Levin, Ph.D.

Non-Executive Independent Director

--

수익 분석

데이터 없음

데이터 없음

사업별

지역별

데이터 없음

주식 보유 통계

마지막 업데이트: Fri, May 16

주주

주주 유형

주주

비율

Ben-Noon (Alon)

13.24%

Rimon Gold Assets Ltd

9.60%

Gordon Ariel S

4.31%

Eisenberg (Or)

2.00%

Tracik (Ferenc)

0.79%

Other

70.05%

주주

비율

Ben-Noon (Alon)

13.24%

Rimon Gold Assets Ltd

9.60%

Gordon Ariel S

4.31%

Eisenberg (Or)

2.00%

Tracik (Ferenc)

0.79%

Other

70.05%

주주 유형

주주

비율

Individual Investor

21.38%

Corporation

9.60%

Investment Advisor

0.29%

Research Firm

0.21%

Venture Capital

0.14%

Hedge Fund

0.11%

Investment Advisor/Hedge Fund

0.07%

Other

68.21%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

37

7.63M

31.79%

+136.65K

2025Q1

39

7.45M

37.28%

+353.50K

2024Q4

38

7.90M

34.02%

+1.29M

2024Q3

32

5.18M

22.45%

-1.31M

2024Q2

35

6.62M

30.57%

+1.57M

2024Q1

38

5.18M

33.20%

-953.28K

2023Q4

38

5.12M

32.81%

-1.05M

2023Q3

33

5.76M

47.99%

-945.27K

2023Q2

33

6.46M

53.11%

+1.06M

2023Q1

30

5.11M

43.34%

-185.85K

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

Ben-Noon (Alon)

3.18M

13.24%

+93.67K

+3.04%

Apr 07, 2025

Rimon Gold Assets Ltd

2.30M

9.6%

+2.30M

--

Dec 02, 2024

Gordon Ariel S

1.03M

4.31%

+1.30K

+0.13%

Dec 31, 2023

Eisenberg (Or)

480.92K

2%

+20.92K

+4.55%

Apr 07, 2025

Tracik (Ferenc)

189.62K

0.79%

+66.67K

+54.22%

Apr 07, 2025

Russek-Blum (Niva)

75.43K

0.31%

+10.00K

+15.28%

Apr 07, 2025

Leuchtenberger (Mark W)

64.00K

0.27%

--

Apr 07, 2025

Morgan Stanley & Co. LLC

50.50K

0.21%

-52.08K

-50.77%

Mar 31, 2025

Meitav Dash Investments Ltd.

40.00K

0.17%

--

Mar 31, 2025

XTX Markets LLC

33.71K

0.14%

-8.19K

-19.55%

Mar 31, 2025

1.160USD

Neurosense Therapeutics Ltd

1.160

개요

회사

금융